Replies to post #193937 on Biotech Values

[DewDiligence]

BNTC's lead program—TT-034 gene therapy for HCV—won't fly, IMO. Having foreign DNA permanently residing in host nuclei seems like an unwarranted safety risk when you can cure the disease with 12 weeks of oral therapy.

BNTC says TT-034 has the benefit of preventing re-infection, but that’s an over-engineered solution to a minor problem.

p.s. On the roadshow webcast, the CEO asserted that BNTC’s US IPO is justified by ALNY’s lofty valuation, LOL.